Product News: bioMérieux Extends Portfolio of Full Microbiology Lab Automation Solutions at ASM General Meeting

24 May 2010

bioMérieux announces that it will present an expanded portfolio of microbiology laboratory automation solutions during the 110th General Meeting of the American Society for Microbiology (ASM) in San Diego, Calif.

  • Myla™: revolutionary new informatics solution to improve lab workflow, information management and instrument connectivity.
  • NucliSENS® EasyQ® MRSA: molecular based test for MRSA, one of the most prevalent multi-drug resistant bacteria.
  • VITEK® 2 PC 5.01: clinical information software that enables more rapid and informative antibiotic susceptibility testing results (AST) for clinicians.
  • chromIDTM VRE and MRSA: chromogenic culture media for leading causes of HAI.
  • Mass Spectrometry: new solution for bacterial identification.

bioMérieux’s chief executive officer, Stéphane Bancel, will present Myla™ for the first time in North America on Monday, May 24. Myla is an innovative laboratory informatics solution that consolidates and transforms microbiology laboratory data into actionable information for patient treatment decisions – while optimizing lab productivity.

“Time-to-treatment is critical when dealing with today’s multi-drug resistant organisms,” said Bancel. “bioMérieux’s new informatic solution, Myla, will transform the way microbiologists work today, significantly improving operational efficiency and making the most relevant information readily available to clinicians so they can take action rapidly. This latest innovation is yet another testimony to our commitment to deliver full microbiology laboratory automation,” he added.

bioMérieux is driving the fight against healthcare-associated infections, broadening its range of microbiology solutions to include NucliSENS® EasyQ® MRSA, a molecular assay for the rapid screening of methicillin-resistant Staphylococcus aureus, one of the most pervasive sources for high-morbidity healthcare-associated infections (HAI) in U.S. hospitals.1 This new assay, which is soon to be submitted for FDA clearance, is CE marked and already available in Europe where it is used for MRSA colonization screening. With NucliSENS EasyQ MRSA and chromID™ MRSA, bioMérieux will offer customers the most flexible and complete solution to effectively manage MRSA, spanning manual and automated techniques.

bioMérieux will also showcase its new mass spectrometry solution featuring a platform for MALDI-ToF based identification, from Japanese leader, Shimadzu, as well as an extensive library of microorganisms, recently acquired from AnagnosTec, compatible with the Shimadzu system.

In conjunction with the events occurring during the ASM General Meeting, the company will host a FutureLab Symposium, May 24 at the San Diego Marriott Hotel and Marina. The symposium will be moderated by Joel Mortsensen, Ph.D., Cincinnati Children’s Hospital, and promises to stimulate the audience with new approaches, experiences and visions for creating a microbiology lab of the future. Along with Dr. Mortensen, the symposium will feature industry experts including:

Joseph Campos, Ph.D. – Director, Microbiology and Molecular Laboratories and Laboratory Informatics, Children’s National Medical Center
Linda Bruno, M.A., MT (ASCP) – Associate Administrative Director, University of Illinois Medical Center